- Home
- VOR vs MGNX Comparison
VOR vs MGNX Comparison
Compare VOR & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- MGNX
- Stock Information
- Founded
- VOR 2015
- MGNX 2000
- Country
- VOR United States
- MGNX United States
- Employees
- VOR N/A
- MGNX N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- MGNX Health Care
- Exchange
- VOR Nasdaq
- MGNX Nasdaq
- Market Cap
- VOR 134.8M
- MGNX 125.2M
- IPO Year
- VOR 2021
- MGNX 2013
- Fundamental
- Price
- VOR $0.72
- MGNX $1.27
- Analyst Decision
- VOR Strong Buy
- MGNX Hold
- Analyst Count
- VOR 7
- MGNX 10
- Target Price
- VOR $9.43
- MGNX $6.83
- AVG Volume (30 Days)
- VOR 269.5K
- MGNX 691.0K
- Earning Date
- VOR 03-20-2025
- MGNX 03-20-2025
- Dividend Yield
- VOR N/A
- MGNX N/A
- EPS Growth
- VOR N/A
- MGNX N/A
- EPS
- VOR N/A
- MGNX N/A
- Revenue
- VOR N/A
- MGNX $149,962,000.00
- Revenue This Year
- VOR N/A
- MGNX N/A
- Revenue Next Year
- VOR N/A
- MGNX $42.52
- P/E Ratio
- VOR N/A
- MGNX N/A
- Revenue Growth
- VOR N/A
- MGNX 155.26
- 52 Week Low
- VOR $0.63
- MGNX $1.17
- 52 Week High
- VOR $2.43
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- VOR 28.48
- MGNX 19.69
- Support Level
- VOR $0.75
- MGNX $1.89
- Resistance Level
- VOR $0.93
- MGNX $2.24
- Average True Range (ATR)
- VOR 0.07
- MGNX 0.17
- MACD
- VOR 0.00
- MGNX -0.08
- Stochastic Oscillator
- VOR 7.61
- MGNX 7.60
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).